BioLineRx Financial Statements From 2010 to 2025

Stocks . USA . 
Stock . BioLineRx
BLRX Stock  USD 0.10  0.02  16.67%   
BioLineRx financial statements provide useful quarterly and yearly information to potential BioLineRx investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on BioLineRx financial statements helps investors assess BioLineRx's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting BioLineRx's valuation are summarized below:
Gross Profit
11 M
Profit Margin
(1.77)
Market Capitalization
20.5 M
Enterprise Value Revenue
0.9493
Revenue
17 M
We have found one hundred twenty available fundamental signals for BioLineRx, which can be analyzed and compared to other ratios and to its rivals. All investors should make sure to validate all of BioLineRx prevailing market performance against the performance between 2010 and 2025 to make sure the company can sustain itself down the road. Enterprise Value is likely to rise to about 105.4 M in 2025, whereas Market Cap is likely to drop slightly above 68.4 M in 2025.

BioLineRx Total Revenue

4.1 Million

Check BioLineRx financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among BioLineRx's main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.7 M, Interest Expense of 2.6 M or Selling General Administrative of 20.1 M, as well as many indicators such as Price To Sales Ratio of 10.09, Dividend Yield of 0.0 or PTB Ratio of 7.44. BioLineRx financial statements analysis is a perfect complement when working with BioLineRx Valuation or Volatility modules.
  
Check out the analysis of BioLineRx Correlation against competitors.
For more information on how to buy BioLineRx Stock please use our How to Invest in BioLineRx guide.

BioLineRx Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets53.7 M73.5 M50.7 M
Slightly volatile
Other Current Liabilities3.2 M3 M1.6 M
Very volatile
Total Current Liabilities37.3 M35.5 M12 M
Slightly volatile
Total Stockholder Equity14.4 M15.2 M32 M
Very volatile
Other Liabilities2.2 M2.1 M2 M
Pretty Stable
Accounts Payable13.1 M12.5 M5.6 M
Slightly volatile
Cash3.6 M3.8 M9.2 M
Slightly volatile
Long Term Debt8 M7.6 M3.6 M
Slightly volatile
Common Stock Shares Outstanding77.6 M73.9 M22.8 M
Slightly volatile
Short Term Investments28.6 M44.5 M27.3 M
Slightly volatile
Other Current Assets1.3 M1.4 M5.8 M
Very volatile
Total Liabilities61.2 M58.3 M20 M
Slightly volatile
Intangible Assets10.4 M17.1 M10 M
Slightly volatile
Common Stock37.9 M36.1 M11.2 M
Slightly volatile
Property Plant Equipment2.1 M2.6 M2 M
Slightly volatile
Short and Long Term Debt Total14 M13.3 M5.3 M
Slightly volatile
Property Plant And Equipment Net2.2 M2.2 M2 M
Slightly volatile
Current Deferred Revenue15.6 M14.9 M5.1 M
Slightly volatile
Non Current Assets Total13.7 M19.3 M12.3 M
Slightly volatile
Cash And Short Term Investments39.3 M49.4 M36.2 M
Slightly volatile
Net Receivables430 K637.2 K566.2 K
Pretty Stable
Common Stock Total Equity11.9 M11.4 M4.9 M
Slightly volatile
Liabilities And Stockholders Equity54.1 M73.5 M49.8 M
Slightly volatile
Non Current Liabilities Total24 M22.8 M8 M
Slightly volatile
Other Stockholder Equity255.4 M408.8 M237.7 M
Slightly volatile
Property Plant And Equipment Gross9 M8.5 M3.4 M
Slightly volatile
Total Current Assets40.4 M54.3 M37.5 M
Slightly volatile
Short Term Debt4.4 M4.2 M1.6 M
Slightly volatile
Net Tangible Assets22.1 M41.7 M27.5 M
Slightly volatile
Short and Long Term Debt3.8 M3.6 M1.4 M
Slightly volatile
Net Invested Capital37.5 M20.7 M47.4 M
Slightly volatile
Net Working Capital23.2 M14.7 M34.1 M
Slightly volatile
Capital Stock37.9 M36.1 M12.2 M
Slightly volatile
Long Term Debt Total6 M6.8 M7.4 M
Slightly volatile
Capital Surpluse212.8 M239.3 M261 M
Slightly volatile
Capital Lease Obligations2.1 M2.1 M2 M
Pretty Stable

BioLineRx Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Interest Expense2.6 M2.5 M961.8 K
Slightly volatile
Selling General Administrative20.1 M19.1 M6.7 M
Slightly volatile
Selling And Marketing Expenses17.6 M16.8 M4.3 M
Slightly volatile
Other Operating Expenses65.8 M62.7 M29.4 M
Slightly volatile
Research Development17.3 M14.4 M15.8 M
Slightly volatile
Total Operating Expenses61.3 M58.4 M28.2 M
Slightly volatile
Interest Income2.4 M2.3 M1.3 M
Very volatile
Reconciled Depreciation886.4 K1.6 M717.9 K
Slightly volatile

BioLineRx Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation1.6 M2.7 M1.6 M
Slightly volatile
Begin Period Cash Flow9.4 M9.5 M11.4 M
Slightly volatile
Depreciation1.7 M1.6 M733.3 K
Slightly volatile
Capital Expenditures324.5 K341.6 K1.3 M
Very volatile
End Period Cash Flow3.6 M3.8 M9.2 M
Slightly volatile
Sale Purchase Of Stock16.2 M18.3 M18.9 M
Very volatile
Issuance Of Capital Stock22.8 M16.2 M12.1 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio10.0919.5319.7027
Very volatile
PTB Ratio7.447.092.8947
Slightly volatile
Days Sales Outstanding21.7824.526.7126
Slightly volatile
Book Value Per Share0.0150.01580.5672
Slightly volatile
Average Payables2.2 M2.5 M2.7 M
Slightly volatile
Stock Based Compensation To Revenue0.460.440.4527
Slightly volatile
Capex To Depreciation0.180.192.4222
Very volatile
PB Ratio7.447.092.8947
Slightly volatile
EV To Sales18.5820.9122.7938
Slightly volatile
Inventory Turnover1.511.71.8547
Slightly volatile
Days Of Inventory On Hand154174189
Slightly volatile
Payables Turnover0.270.310.3335
Slightly volatile
Sales General And Administrative To Revenue3.283.123.2243
Slightly volatile
Research And Ddevelopement To Revenue1.242.352.3738
Very volatile
Capex To Revenue0.0330.05570.0571
Very volatile
Cash Per Share0.04880.05130.6439
Slightly volatile
Days Payables Outstanding8609671.1 K
Slightly volatile
Income Quality0.410.431.1544
Slightly volatile
Intangibles To Total Assets0.140.210.1603
Slightly volatile
Current Ratio1.671.765.4707
Slightly volatile
Receivables Turnover10.7312.0713.1568
Slightly volatile
Graham Number0.150.162.1155
Slightly volatile
Shareholders Equity Per Share0.0150.01580.5672
Slightly volatile
Debt To Equity0.830.790.2334
Slightly volatile
Capex Per Share3.0E-44.0E-40.0184
Slightly volatile
Revenue Per Share0.00540.00570.1661
Slightly volatile
Interest Debt Per Share0.03190.01640.0328
Pretty Stable
Debt To Assets0.170.160.0806
Slightly volatile
Operating Cycle176198216
Slightly volatile
Price Book Value Ratio7.447.092.8947
Slightly volatile
Days Of Payables Outstanding8609671.1 K
Slightly volatile
Ebt Per Ebit0.751.10.9388
Slightly volatile
Company Equity Multiplier4.574.351.9988
Slightly volatile
Long Term Debt To Capitalization0.320.30.1065
Slightly volatile
Total Debt To Capitalization0.440.420.1445
Slightly volatile
Debt Equity Ratio0.830.790.2334
Slightly volatile
Quick Ratio1.61.696.6988
Slightly volatile
Net Income Per E B T1.091.151.0423
Pretty Stable
Cash Ratio0.150.161.1796
Slightly volatile
Days Of Inventory Outstanding154174189
Slightly volatile
Days Of Sales Outstanding21.7824.526.7126
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio0.860.911.0391
Pretty Stable
Price To Book Ratio7.447.092.8947
Slightly volatile
Fixed Asset Turnover2.032.292.4946
Slightly volatile
Debt Ratio0.170.160.0806
Slightly volatile
Price Sales Ratio10.0919.5319.7027
Very volatile
Asset Turnover0.06010.06760.0737
Slightly volatile
Gross Profit Margin0.250.270.2684
Slightly volatile
Price Fair Value7.447.092.8947
Slightly volatile

BioLineRx Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap68.4 M119.8 M66.2 M
Pretty Stable
Enterprise Value105.4 M100.4 M58.9 M
Slightly volatile

BioLineRx Fundamental Market Drivers

Cash And Short Term Investments43 M

BioLineRx Upcoming Events

27th of March 2024
Upcoming Quarterly Report
View
22nd of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
27th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About BioLineRx Financial Statements

BioLineRx investors use historical fundamental indicators, such as BioLineRx's revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in BioLineRx. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue14.9 M15.6 M
Total Revenue4.3 M4.1 M
Cost Of Revenue3.3 M4.4 M
Stock Based Compensation To Revenue 0.44  0.46 
Sales General And Administrative To Revenue 3.12  3.28 
Research And Ddevelopement To Revenue 2.35  1.24 
Capex To Revenue 0.06  0.03 
Revenue Per Share 0.01  0.01 
Ebit Per Revenue(11.91)(11.31)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
BTCBitcoin
TRXTRON
BNBBinance Coin

Additional Tools for BioLineRx Stock Analysis

When running BioLineRx's price analysis, check to measure BioLineRx's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioLineRx is operating at the current time. Most of BioLineRx's value examination focuses on studying past and present price action to predict the probability of BioLineRx's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioLineRx's price. Additionally, you may evaluate how the addition of BioLineRx to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY